Shots:

• The P-IIb study evaluates the efficacy & safety of remibrutinib vs PBO in 311 patients with CSU inadequately controlled by H1-antihistamines for 12wks.
• The results showed an improvement in UAS7 related to CFB @4 & 12wks. & rapid improvement as of 1wks.- patients achieved UAS7=0 (complete absence of hives & itch) and UAS7≤6 (well-controlled disease activity)- favorable safety profile & good tolerability across all doses with no dose-dependent pattern. The therapy showed significant dose-response related to CFB in UAS7 score @4wks.
• Remibrutinib is a highly selective- potent BTK inhibitor. The company is expected to start P-III studies of remibrutinib in CSU at the end of 2021

  Ref: Novartis | Image: Novartis